Aquestive Therapeutics Resubmits FDA Application for Anaphylm Sublingual Film

Key Facts

In a move reflecting the ongoing efforts to develop innovative therapeutic solutions for medical emergencies, Aquestive Therapeutics has announced the resubmission of its New Drug Application (NDA) for Anaphylm to the U.S. FDA. This action aims to secure approval for the sublingual film designed to treat Type I allergic reactions. The resubmission is supported by positive topline human factors and pharmacokinetic study results achieved in August 2026, which addressed previous regulatory requirements.

This resubmission represents a critical regulatory milestone for the biotech firm, as future success hinges on the FDA's review timeline and its interpretation of the updated data. According to market data, AQST stock closed at $4.82 on September 16, 2026, having traded between a low of $4.74 and a high of $4.95 during that session. These price levels reflect investor anticipation regarding the regulatory outcome which could expand the company's commercial footprint in the allergy treatment sector.

Looking ahead, traders are monitoring AQST support and resistance levels around the $4.74 to $4.95 range based on the close as of September 16, 2026. In the absence of major upcoming economic calendar events directly impacting the pharmaceutical sector, the primary catalyst remains any official FDA communication regarding the acceptance of the filing or the establishment of a formal review goal date.